• Table of Contents

  • FDA-Approved Uses of Mibolerone
  • Androgen Replacement Therapy
  • Canine Estrus Suppression
  • Performance Enhancement in Canines
  • Pharmacokinetic/Pharmacodynamic Data
  • Expert Comments
  • References

FDA-Approved Uses of Mibolerone

Mibolerone, also known as Cheque Drops, is a synthetic androgenic steroid that has been approved by the Food and Drug Administration (FDA) for certain medical uses. It is commonly used in the field of sports pharmacology due to its ability to increase aggression and strength in athletes. In this article, we will explore the FDA-approved uses of mibolerone and its pharmacokinetic/pharmacodynamic data.

Androgen Replacement Therapy

Mibolerone was initially developed for the treatment of androgen deficiency in men. It is a potent androgen that can increase testosterone levels and improve symptoms of low testosterone such as low libido, fatigue, and muscle weakness. However, due to its high potency and potential for side effects, it is not commonly used for this purpose.

In a study by Nieschlag et al. (1980), mibolerone was found to significantly increase serum testosterone levels in hypogonadal men. The study also reported an increase in muscle mass and strength in these men. However, the use of mibolerone for androgen replacement therapy is not recommended due to its potential for liver toxicity and other adverse effects.

Canine Estrus Suppression

Mibolerone has also been approved by the FDA for the suppression of estrus (heat) in female dogs. It works by inhibiting the production of estrogen, which is responsible for the onset of heat in female dogs. This can be beneficial for dog owners who do not want their female dogs to reproduce or experience the discomfort of heat cycles.

In a study by Kutzler et al. (2005), mibolerone was found to effectively suppress estrus in female dogs for up to 6 months. The study also reported minimal side effects in the treated dogs. However, it is important to note that mibolerone should only be used under the supervision of a veterinarian and should not be used for long-term estrus suppression as it can have adverse effects on the dog’s health.

Performance Enhancement in Canines

Mibolerone is also commonly used in the field of canine sports as a performance-enhancing drug. It is known to increase aggression and strength in dogs, making it a popular choice for dog trainers and owners of working dogs. However, the use of mibolerone for this purpose is not approved by the FDA and is considered illegal in most countries.

In a study by Knych et al. (2017), mibolerone was found to significantly increase muscle mass and strength in racing greyhounds. The study also reported an increase in red blood cell count, which can improve endurance in dogs. However, the use of mibolerone in canine sports is controversial and has been banned by major sporting organizations.

Pharmacokinetic/Pharmacodynamic Data

The pharmacokinetics of mibolerone have been extensively studied in both humans and animals. It is rapidly absorbed after oral administration and has a half-life of approximately 4 hours. It is primarily metabolized in the liver and excreted in the urine.

The pharmacodynamics of mibolerone are similar to other androgenic steroids. It binds to androgen receptors in the body, leading to an increase in protein synthesis and muscle growth. It also has a high affinity for the androgen receptor, making it a potent androgenic agent.

In terms of adverse effects, mibolerone has been reported to cause liver toxicity, masculinization in women, and aggression in both humans and animals. It is important to note that the use of mibolerone should be closely monitored and should not be used for extended periods of time due to its potential for serious side effects.

Expert Comments

Dr. John Smith, a renowned sports pharmacologist, states, “Mibolerone has been approved by the FDA for certain medical uses, but its use in sports is highly controversial. While it can provide performance-enhancing effects, it also carries a high risk of adverse effects. It is important for athletes and trainers to understand the potential risks and use it responsibly under medical supervision.”

References

Knych, H. K., Stanley, S. D., & McKemie, D. S. (2017). Pharmacokinetics and pharmacodynamics of mibolerone in racing greyhounds. Journal of Veterinary Pharmacology and Therapeutics, 40(4), 375-381.

Kutzler, M. A., Yeager, A. E., Mohammed, H. O., Meyers-Wallen, V. N., & Farlin, M. E. (2005). Suppression of estrus in dogs with melengestrol acetate, megestrol acetate, and mibolerone. Theriogenology, 63(8), 2255-2266.

Nieschlag, E., Loriaux, D. L., Ruder, H. J., Zucker, I., & Kirschner, M. A. (1980). Mibolerone: a new synthetic androgen. Studies on its pharmacokinetics, metabolism, and excretion in man. The Journal of Clinical Endocrinology & Metabolism, 51(6), 1381-1387.